Table 2.
A selection of prospective trials and retrospective studies with a substantial number of ipsilateral local recurrences (either in situ or invasive) after breast‐conserving surgery for DCIS, with or without adjuvant radiotherapy and/or hormonal therapy
| Ref | Study /trial | FU time (months)1 Mean Median | Total number of patients n | Overall recurrence n (%) | In situ recurrence n (%) | Invasive recurrence n (%) | No radiotherapy, no TAM | Radiotherapy without TAM | Radiotherapy with TAM | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| In situ recurrence n (%) | Invasive recurrence n (%) | In situ recurrence n (%) | Invasive recurrence n (%) | In situ recurrence n (%) | Invasive recurrence n (%) | |||||||
| 20 | NSABP B‐17 | 207 | 813 | 222 (27) | 99 (12) | 123 (15) | 62 (15) | 79 (20) | 37 (9) | 44 (11) | NA | NA |
| 20 | NSABP B‐24 | 163 | 1,799 | 268 (15) | 128 (7) | 140 (8) | NA | NA | 68 (8) | 81 (9) | 60 (7) | 59 (7) |
| 90 | SweDCIS | 204 | 1,046 | 258 (25) | 129 (12) | 129 (12) | 91 (17) | 74 (14) | 38 (7) | 55 (11) | NA | NA |
| 19 | UK/ANZ DCIS2 | 152 | 1,694 | 376 (22) | 197 (12) | 163 (10) | 86 (16) | 52 (10) | 14 (5) | 10 (4) | 11 (3) | 11 (3) |
| 17 | EORTC10853 | 190 | 1,010 | 234 (23) | 110 (11) | 121 (12) | 74 (15) | 75 (15) | 37 (7) | 48 (10) | NA | NA |
| 24 | Sloane project | 64 | 7,007 | 368 (5) | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| 70 | Pruneri et al. | 98 | 945 | 180 (19) | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| 41 | Punglia et al. | 60 | 2,762 | 79 (3) | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| 91 | E5194 cohort | 138 | 327 | 53 (16) | 26 (8) | 27 (8) | 3 | 3 | 3 | 3 | 3 | 3 |
| 91 | Ontario cohort | 118 | 446 | 65 (15) | 27 (6) | 38 (9) | 3 | 3 | 3 | 3 | 3 | 3 |
| 95 | Toss et al. | 103 | 776 | 83 (11) | 30 (4) | 53 (7) | 3 | 3 | 3 | 3 | 3 | 3 |
| 97 | Wai et al. | 113 | 460 | 60 (13) | 32 (7) | 28 (6) | 32 (7) | 28 (6) | NA | NA | NA | NA |
| 96 | Tunon‐de‐Lara et al. | 118 | 812 | 71 (9) | 24 (3) | 47 (6) | 3 | 3 | 3 | 3 | 3 | 3 |
| 92 | Butler‐Henderson et al. | 113 | 1,356 | 235 (17) | 86 (6) | 149 (11) | 3 | 3 | 3 | 3 | 3 | 3 |
| 93 | Collins et al. | 58 | 2,995 | 325 (11) | 172 (6) | 153 (5) | 3 | 3 | 3 | 3 | 3 | 3 |
| 94 | Rudloff et al. | 67 | 1,868 | 202 (11) | 122 (7) | 80 (4) | 3 | 3 | 3 | 3 | 3 | 3 |
Some study reports provided median follow‐up time in years; for these reports, the number of years was multiplied by 12 months to achieve median follow‐up in months to enable comparison.
The category “tamoxifen alone, without radiotherapy” from this report is not included in this table.
No details on different subgroups were provided in these study reports, and therefore data on different subgroups could not be provided in this table.
Abbreviations: DCIS, ductal carcinoma in situ; EORTC, European Organization for Research and Treatment of Cancer; FU, follow‐up; NA, not applicable; NSABP, National Surgical Adjuvant Breast and Bowel Project; Ref, reference number; TAM, tamoxifen; UK/ANZ, United Kingdom/Australia, New Zealand.
Bold values are means and values in italics are medians.